Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

Inclusion Criteria:

Clinical diagnosis of HF requiring chronic treatment of loop diuretics
Left Ventricular Ejection Fraction (LVEF) ≤ 40% at screening by echocardiography
N-Terminal-prohormone of Brain Natriuretic Peptide (NT-proBNP) ≥400 pg/mL at screening for patients without atrial fibrillation or atrial flutter, or, NT-proBNP ≥ 1,200 pg/mL at screening for patients with atrial fibrillation or atrial flutter
Treated for Heart Failure with stable, optimal pharmacological therapy
Acceptable screening echocardiographic image quality

Exclusion Criteria:

Female patients of childbearing potential
Patients with a New York Heart Association (NYHA) Class I or IV
Heart failure that is clearly caused by toxin / drug such as Adriamycin
Significant medical conditions or recent history suggesting the patient's study participation will potentially pose a major risk to patient's safety and well-being
Need for routine scheduled outpatient IV infusions for Heart Failure or scheduled ultrafiltration
History of rhabdomyolysis or history of autoimmune diseases
Severe renal disease
Hepatic disease
Pulmonary disease limiting exercise capacity
Atrial fibrillation with rapid ventricular response
Life expectancy of less than 6 months
Type 1 diabetes mellitus or Type 2 diabetes mellitus with very poor glycemic control
Patients with anemia